Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cumberland Pharmaceuticals Inc

NASDAQ: CPIX · Life Sciences · 8 alerts · CIK 1087294

Share price
$5.21Close, Nov 16
Market cap
$78.1M
Shares outstanding
15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cumberland Pharmaceuticals Inc filings on SEC EDGAR ↗

4:28 PM ET 8-K/A
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). The study met its primary objective of demonstrating that ifetroban was generally well tolerated with a safety profile consistent with prior experience, though the trial was not powered to detect significant efficacy differences due to limited disease progression in both groups.

Term
12 months
4:28 PM ET 8-K/A
Business Update

Cumberland Pharmaceuticals Business Update

Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The FDA has granted a rolling submission for the application, which will use data from the FIGHT DMD trial compared against natural history databases. The decision to file follows several regulatory meetings where the company addressed FDA questions regarding Phase 2 study results and efficacy endpoints.

5:15 PM ET 10-Q
Financial Results

Cumberland Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $77.8M

Cumberland Pharmaceuticals reported a significant net income of $77.8 million for the quarter ended September 30, 2026, primarily driven by an $81.1 million gain from the disposal of discontinued operations. Total revenue from continuing operations increased to $2.2 million, while the company declared a substantial cash dividend of $22.5 million during the period.

Key figure
Net income $77.8M
5:07 PM ET 8-K
Financial Results

Cumberland Pharmaceuticals Financial Results

Cumberland Pharmaceuticals reported Q3 2026 financial results, its first full quarter as a development-focused company following the $100 million divestiture of its commercial brands to Apotex Health. The company announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD) following a successful Phase 2 trial.

Term
Q3 2026

“Our first full quarter as a development-focused company has reinforced the value of concentrating our efforts on our clinical pipeline. Our team and resources are now dedicated to developing new medicines for unmet medical needs. We have the financial strength and the expertise to pursue our new mission, as we work to create lasting value for patients and shareholders.”

A.J. Kazimi, CEO of Cumberland Pharmaceuticals
4:41 PM ET 8-K
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The submission is supported by Phase 2 FIGHT DMD trial data showing a statistically significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group. While the FDA expressed concerns regarding the sufficiency of the data package for efficacy requirements, the company is moving forward with the submission following a pre-NDA meeting.

Counterparty
FDA
5:02 PM ET 8-K
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis. The study results supported the safety and tolerability of the drug candidate in this rare disease population.

9:09 AM ET 8-K/A
Shareholder Meeting

Cumberland Pharmaceuticals Shareholder Meeting

Cumberland Pharmaceuticals reported that following its 2026 Annual Meeting, the Board of Directors determined to hold future advisory votes on executive compensation every three years. This decision aligns with the shareholder preference expressed during the advisory vote at the meeting.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.